BioSpace News Archive

Genialis, a leader in applied data science for the development of precision medicines, today announced a collaborative partnership with Oncologie, an international, clinical-stage biopharma developing next-generation immunotherapies for cancer

InnerScope’s HearingVite™ Dietary Hearing Supplements are specifically designed to maintain hearing health for the 50 million U.S. hearing impaired consumers

RegeneRx Biopharmaceuticals, Inc., a clinical-stage drug development company focused on tissue protection, repair and regeneration, published its annual letter to stockholders on the Company’s website at www.regenerx.com.

Regional Medical Group and Onyx Imaging are expanding. A new medical facility opened in the Dalton area.

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for patent application No. 16/098,338 related to CTP-543, the Company’s investigational treatment for alopecia areata

Profound Medical Corp. (TSX:PRN; NASDAQ: PROF) (“Profound” or the “Company”) is pleased to announce the pricing of an underwritten public offering (the “Offering”) of 2,950,000 common shares of the Company (the “Common Shares”), at a price of US$11.65 per Common Share (the “Offering Price”).

Conformal Medical, Inc. announced today the presentation of the first left atrial appendage closure (LAAC) cases with its unique CLAAS® Technology in patients under conscious sedation without general anesthesia. Drs. Petr Neuzil and Vivek Reddy will present “ICE-Guided Implantation of the Conformal Left Atrial Appendage Closure Device: First Clinical Report” at the AF Symposium meeting in Washington, D.C., January 23-24.

BioNovelus, Inc. (OTC: ONOV) announces that it has hired RSM US LLP (“RSM”) as the firm’s external, PCAOB-qualified auditor.

The Lung Cancer Research Foundation® (LCRF), the largest lung cancer focused foundation in the US supporting lung cancer research, has unveiled its newly revamped website, lcrf.org.

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Allergan plc (NYSE: AGN) announced today that the companies have reached an agreement with Teva Pharmaceuticals, USA (Teva) resolving patent litigation brought in response to Teva’s abbreviated new drug application (ANDA) seeking approval to market generic versions of 145 mcg and 290 mcg LINZESS (linaclotide) prior to the expiration of the companies’ applicable patents.